KYMERA THERAPEUTICS THIRD QUARTER 2026 RESULTS CALL - KYMERA THERAPEUTICS INC

Explicit Guidance:

• No formal financial guidance (revenue, earnings, capex, margins) provided; revenue guidance states "no additional collaboration revenue for the remainder of 2026."
• Cash runway extends into 2029 with current capitalization of $1.6 billion.
• Operating expenses expected to increase "gradually but consistently" in 2027 to support pipeline advancement, with accelerated spending expected upon initiating KT621 Phase 3.

Business-Segment Outlook:

• KT621 (STAT6 Degrader):
  • Atopic Dermatitis (AD): Phase 2b "Broaden" data expected by year-end (FY2026); Phase 3 initiation planned for mid-2027, contingent on data and FDA alignment.
  • Asthma: Phase 2b "BRETT" enrollment progressing; top-line results expected in late 2027.
  • Market Expectation: Management expects KT621 efficacy to be "in the ballpark" of Dupilumab (Dupixent) at week 16. Anticipates potential to expand the market to untreated or poorly treated patients who currently avoid injectables.
• KT579 (IRF5 Degrader):
  • Lupus (SLE): Phase 1b "Lumora" study planned to initiate in patients with lupus by early 2027. Study design involves ~30 patients over 16 weeks to assess biomarker modulation and early clinical signals.
  • Expansion: Plans to expand beyond lupus to other autoimmune indications (e.g., Sjogren's, IBD, RA) in future studies; specific program introductions deferred until next year.
• Collaboration Partners:
  • Sanofi: Advancing KT485 (IREC4 degrader) in Phase 1 healthy volunteer study; no specific milestone dates provided beyond ongoing progress.
  • Gilead: Advancing KT200 (CDK2 molecular glue) in IND-enabling activities; IND planned for 2027.
• Pipeline: Goal to advance one new program to Development Candidate status annually; next program disclosure deferred to next year.

Market and Competitive Outlook:

• AD Market Dynamics: Highlights a significant gap where only ~5% (400,000) of 6–9 million moderate-to-severe US patients receive advanced systemic therapies, largely due to aversion to injectables and box warnings.
• Competitive Landscape: Anticipates KT621 will compete less on pure efficacy replication and more on market expansion by offering a "safe, effective oral" alternative. References successful oral launches in psoriasis (Icotide) and dermatology as precedents for expanding treated populations.
• Differentiation Strategy: Focuses on KT621's potential to treat comorbidities (e.g., asthma, EoE, CRS) simultaneously, leveraging Type 2 inflammation biology.

Macro / Industry Outlook:

• Regulatory Strategy: Emphasizes the need for FDA alignment prior to Phase 3 initiation for KT621.
• Quiet Period: Management has entered a quiet period effective immediately ahead of the STAT6 Phase 2b readout; no commentary on the program will be provided until results are reported.
• Disclosure Limits: Will retain specific dose-response data and competitive differentials (e.g., exact degradation thresholds) for competitive advantage; will share data in a format interpretable for safety/efficacy assessment but may withhold granular comparator metrics until necessary.

Strategic Initiatives:

• Phase 3 Preparation: "Well underway" in preparation for the first AD Phase 3 study, contingent on positive Phase 2b data.
• Team Expansion: Actively adding significant headcount in preparation for Phase 3 operations.
• Technology Focus: Continues to prioritize oral heterobifunctional molecules to displace injectable biologics; explicitly states no intent to pursue injected extracellular degraders.

Risks and Headwinds to Outlook:

• Data Risk: KT621 efficacy "ballpark" expectation is hypothetical and cross-trial comparisons have inherent flaws; actual results could differ materially.
• Safety Signals: Potential for conjunctivitis (mechanistically coherent with IL-4/13 biology) in KT621; potential safety signals related to IRF5 degradation (redundancies in family) will be monitored, though preclinical and Phase 1 data show no infection signals.
• Enrollment Challenges: Higher screen failure rates and stricter inclusion criteria in the Asthma program compared to AD could slow enrollment relative to market demand.
• Clinical Outcome Uncertainty: Phase 1b Lupus study is not powered for clinical endpoints; interpretation of clinical activity in the setting of high placebo rates is complex.
• Timing Risk: Delays in Phase 2b readouts or lack of FDA alignment could shift Phase 3 initiation beyond mid-2027.

Management Tone on the Future:

• Confidence Level: High confidence in the platform's ability to translate preclinical targets to human efficacy ("impeccable human translation," "repeated execution").
• Strategic Clarity: Strong conviction that an oral STAT6 degrader can transform the AD market by treating patients currently on the "sidelines."
• Caution/Hedges: Management consistently reiterates that cross-trial comparisons are scientifically difficult and that efficacy will depend on the actual Phase 2b data; avoids specific numerical efficacy predictions beyond the "Dupilumab ballpark" heuristic.
• Operational Efficiency: Expresses pride in accelerating the AD program by "two quarters" early despite a focus on quality over speed.

Miscellaneous:

• KT579 Phase 1 Results: Achieved >90% median IRF5 degradation in blood and skin; demonstrated robust inhibition of inflammatory cytokines (TNF-alpha, IL-12/23, IL-1 beta), interferon response (up to 98% inhibition), and B-cell biology biomarkers.
• Safety: KT579 Phase 1 showed a safety profile comparable to placebo with no serious adverse events or discontinuations.
• Patient Retention: 98% of eligible patients in the AD Broaden 2 study enrolled in the 52-week open-label extension.